Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tumors recycle glucocorticoids to drive Treg-mediated immunosuppression
Julian Swatler, … , Ana C. Anderson, Enrico Lugli
Julian Swatler, … , Ana C. Anderson, Enrico Lugli
Published September 15, 2023
Citation Information: J Clin Invest. 2023;133(18):e173141. https://doi.org/10.1172/JCI173141.
View: Text | PDF
Commentary Article has an altmetric score of 5

Tumors recycle glucocorticoids to drive Treg-mediated immunosuppression

  • Text
  • PDF
Abstract

Suppression of antitumor immunity is a prominent feature of the tumor microenvironment. In this issue of the JCI, Taves, Otsuka, and authors show that glucocorticoids (GCs), which are potent immunosuppressive hormones mainly produced by the adrenals, can be reconverted from their inactive form to active metabolites via the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme expressed by murine tumor cell lines. In the tumor microenvironment, GCs acted on CD4+ regulatory T cells to enhance their immunosuppressive function and promote tumor growth. The findings suggest that targeting GC recycling as a strategy for modulating tumor immunosuppression has the potential to improve therapeutic efficacy of immune checkpoint blockade.

Authors

Julian Swatler, Young-Jun Ju, Ana C. Anderson, Enrico Lugli

×

Figure 1

Tumors recycle GCs to drive Treg-mediated immunosuppression.

Options: View larger image (or click on image) Download as PowerPoint
Tumors recycle GCs to drive Treg-mediated immunosuppression.
The murine ...
The murine B16 tumor cell lines express 11β-HSD1 to convert inactive GCs to their active metabolites (6). Within the tumor microenvironment of immunocompetent mice, GCs act on CD4+ Tregs to enhance their immunosuppressive function (6) and on CD8+ T cells to impede function (2), thereby promoting tumor growth. 11β-HSD1–producing B16 tumor cells in Rag2-deficient mice, which lack T and B cells, cease to expand, suggesting that GCs act locally on adaptive immune cells to promote tumor growth.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 8 X users
On 1 Facebook pages
9 readers on Mendeley
See more details